National Cancer Institute (NCI): Neoplasms, Unknown Primary trials

The registry lists 18 Neoplasms, Unknown Primary studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 10Phase 2 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00387335Phase 2Results posted
• SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00095628Phase 2Results posted
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00906360Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1